Sonia Arguello
Research Subjects
Research Interests
Sonia Arguello has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Eva Harris
Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA
4 shared publications - Angel Balmaseda
Sustainable Sciences Institute
3 shared publications - Aubree Gordon
Department of Epidemiology, School of Public Health, University of Michigan
3 shared publications - Damaris Collado
Sustainable Sciences Institute
3 shared publications - Guillermina Kuan
Sustainable Sciences Institute, Managua, Nicaragua
3 shared publications - Fausto Andres Bustos Carrillo
Division of Infectious Diseases and Vaccinology, School of Public Health, University of California
2 shared publications
Latest Publications
- Open Access
Spatial analyses of infection and disease during chikungunya and Zika epidemics in Managua, Nicaragua
Chikungunya (CHIKV) and Zika (ZIKV) viruses have caused widespread epidemics across the Americas. After several years of minimal transmission, CHIKV is once again spreading in Nicaragua. We investigated spatial aspects of two chikungunya epidemics (2014, 2015) and one Zika epidemic (2016) in a prospective pediatric cohort in Nicaragua. We used generalized estimating equations, generalized additive and mixed-effects models, Kuldorff’s scan statistic, and intracluster correlations to analyze the infection and disease status of ∼3,000 initially uninfected participants during each epidemic. We found that the incidence of infection (# new infections/total population) and disease (# new cases/total population) often had different spatial patterns, demonstrating that high-infection areas may not exhibit much disease. High infection incidence was observed near a large cemetery west of the study site. The large 2015 chikungunya epidemic and 2016 Zika epidemic started near the cemetery, exhibited high infection incidence throughout the study site, and had extensive month-to-month changes in spatiotemporal dynamics. Clusters of excess infections were large and adjacent to the cemetery, while clusters of excess uninfected participants were found in the northern and eastern sections of the study area. Notably, the intracluster correlation of infection was very weak in households (∼0.2), and infection status was correlated across distances <200 meters. Similarities across the epidemics suggest that targeting interventions to the built, non-household environment may reduce epidemic potential in Managua. Overall, spatial analyses of epidemics that only use case data may substantially underestimate the full extent of viral transmission, missing identification of high-infection areas and opportunities for intervention.
Open AccessSpatial analyses of infection and disease during chikungunya and Zika epidemics in Managua, Nicaragua
Chikungunya (CHIKV) and Zika (ZIKV) viruses have caused widespread epidemics across the Americas. After several years of minimal transmission, CHIKV is once again spreading in Nicaragua. We investigated spatial aspects of two chikungunya epidemics (2014, 2015) and one Zika epidemic (2016) in a prospective pediatric cohort in Nicaragua. We used generalized estimating equations, generalized additive and mixed-effects models, Kuldorff’s scan statistic, and intracluster correlations to analyze the infection and disease status of ∼3,000 initially uninfected participants during each epidemic. We found that the incidence of infection (# new infections/total population) and disease (# new cases/total population) often had different spatial patterns, demonstrating that high-infection areas may not exhibit much disease. High infection incidence was observed near a large cemetery west of the study site. The large 2015 chikungunya epidemic and 2016 Zika epidemic started near the cemetery, exhibited high infection incidence throughout the study site, and had extensive month-to-month changes in spatiotemporal dynamics. Clusters of excess infections were large and adjacent to the cemetery, while clusters of excess uninfected participants were found in the northern and eastern sections of the study area. Notably, the intracluster correlation of infection was very weak in households (∼0.2), and infection status was correlated across distances <200 meters. Similarities across the epidemics suggest that targeting interventions to the built, non-household environment may reduce epidemic potential in Managua. Overall, spatial analyses of epidemics that only use case data may substantially underestimate the full extent of viral transmission, missing identification of high-infection areas and opportunities for intervention.
- Open Access
A comparative analysis of dengue, chikungunya, and Zika in a pediatric cohort over 18 years
Background Dengue, chikungunya, and Zika are mosquito-borne diseases of major human concern. Differential diagnosis is complicated in children and adolescents by their overlapping clinical features (signs, symptoms, and complete blood count results). Few studies have directly compared the three diseases. We assessed clinical features of cases aged 2-17 years experiencing these diseases. Methods We characterized 1,405 dengue, 517 chikungunya, and 522 Zika pediatric cases occurring from January 2006 through December 2023 in a Nicaraguan cohort study. Clinical records and laboratory results across the first 10 days of illness were examined from a primary care health center. All cases were laboratory-confirmed. Data were analyzed with generalized additive models, generalized mixed models, and machine learning models. Findings The prevalence of many clinical features exhibited by dengue, chikungunya, and Zika cases differed substantially overall, by age, and by day of illness. Dengue cases were differentiated most by abdominal pain, leukopenia, nausea/vomiting, and basophilia; chikungunya cases were differentiated most by arthralgia and the absence of leukopenia and papular rash; and Zika cases were differentiated most by rash and lack of fever and lymphocytopenia. Dengue and chikungunya cases exhibited similar temperature dynamics during acute illness, and their temperatures were higher than Zika cases. Sixty-two laboratory-confirmed afebrile dengue cases, which would not be captured by any widely used international case definition, presented very similarly to afebrile Zika cases, though some exhibited warning signs of disease severity. The presence of arthralgia, the presence of basophilia, and the absence of fever were the most important model-based predictors of chikungunya, dengue, and Zika, respectively. Interpretations These findings substantially update our understanding of dengue, chikungunya, and Zika in children while identifying various clinical features that could improve differential diagnoses. The occurrence of afebrile dengue warrants reconsideration of current case definitions. Funding US National Institutes of Health R01AI099631, P01AI106695, U01AI153416, U19AI118610. Research in context Evidence before this study: Dengue, chikungunya, and Zika are mosquito-borne diseases that co-occur in tropical and subtropical settings and give rise to fever, rash, and a variety of other clinical features. We reviewed the most widely used international case definitions for the three diseases – established by either the World Health Organization (WHO) or the Pan American Health Organization (PAHO); PAHO’s 2022 report on differential diagnosis and treatment options for dengue, chikungunya, and Zika; and the 80 studies underlying PAHO’s diagnostic recommendations. The available evidence suggests that dengue, chikungunya, and Zika have a broad and overlapping set of clinical manifestations that hamper differential diagnosis, and hence case management, in the absence of definitive laboratory testing. This similarity in disease presentation is believed to be especially characteristic of the first few days of illness. Most of the studies on the diseases’ clinical manifestations are in adult populations, and these studies constitute the main evidence base for the existing case definitions. For example, only one of the 80 studies summarized in PAHO’s recent report provided direct comparisons of the clinical features across cases experiencing dengue, chikungunya, and Zika, and that study mainly focused on adults. Disease presentation is more non-specific in children and adolescents than in adults, further impeding differential diagnoses in pediatric populations. Current guidelines suggest that the presence of thrombocytopenia, progressive increases in hematocrit, and leukopenia tend to distinguish dengue from chikungunya and Zika; that arthralgia is more common in chikungunya; and that pruritis is more common in Zika. Fever is considered a defining feature of dengue, such that all case definitions in widespread use for the disease require that patients exhibit fever. However, existing but limited evidence suggests that dengue cases can very rarely present without fever. Added value of this study: This study follows a cohort of Nicaraguan children through multiple dengue epidemics, two large chikungunya epidemics, and one explosive Zika epidemic. By synthesizing 18 years’ worth of primary care medical records, we find clinically meaningful differences in the prevalence of many clinical features, including by day of illness and across age, but not by sex. In addition to verifying the clinical features PAHO identified as key distinguishing features, we also identified others, including papular rash, nausea, hemorrhagic manifestations, abdominal pain, and basophilia, that could aid differential diagnoses. As the PAHO report is based on a multitude of studies with varied age ranges, health care accessibility, overall research quality, and patient populations, this study is a complementary and important counterpart that draws from a single, well-characterized source population. Further, we identified 62 laboratory-confirmed cases of afebrile dengue (7·2% of all dengue cases since we started testing any suspected case exhibiting afebrile rash). The disease manifestations of afebrile dengue cases were generally clinically indistinguishable from afebrile Zika, although several displayed warning signs of severity. We found that cases of the three diseases exhibited different temperature dynamics across the acute period of illness. Machine learning models were best able to distinguish chikungunya (an alphaviral disease) from dengue and Zika (flaviviral diseases) based on clinical features alone. Our dengue model performed well, especially in classifying febrile dengue cases. However, our Zika model struggled to properly distinguish afebrile dengue cases from afebrile Zika cases, likely due to their very similar and minimal disease presentation. Implications of all the available evidence: Despite clinical overlap in the pediatric manifestations of dengue, chikungunya, and Zika, we identify meaningful differences in their presentation and in laboratory markers that can be leveraged to improve diagnoses in the absence of definitive laboratory-based diagnostic testing. Afebrile dengue should be studied more and incorporated into future case definitions, as not accounting for its existence can impede surveillance, laboratory testing strategies, clinical management, and research efforts.
Open AccessA comparative analysis of dengue, chikungunya, and Zika in a pediatric cohort over 18 years
Background Dengue, chikungunya, and Zika are mosquito-borne diseases of major human concern. Differential diagnosis is complicated in children and adolescents by their overlapping clinical features (signs, symptoms, and complete blood count results). Few studies have directly compared the three diseases. We assessed clinical features of cases aged 2-17 years experiencing these diseases. Methods We characterized 1,405 dengue, 517 chikungunya, and 522 Zika pediatric cases occurring from January 2006 through December 2023 in a Nicaraguan cohort study. Clinical records and laboratory results across the first 10 days of illness were examined from a primary care health center. All cases were laboratory-confirmed. Data were analyzed with generalized additive models, generalized mixed models, and machine learning models. Findings The prevalence of many clinical features exhibited by dengue, chikungunya, and Zika cases differed substantially overall, by age, and by day of illness. Dengue cases were differentiated most by abdominal pain, leukopenia, nausea/vomiting, and basophilia; chikungunya cases were differentiated most by arthralgia and the absence of leukopenia and papular rash; and Zika cases were differentiated most by rash and lack of fever and lymphocytopenia. Dengue and chikungunya cases exhibited similar temperature dynamics during acute illness, and their temperatures were higher than Zika cases. Sixty-two laboratory-confirmed afebrile dengue cases, which would not be captured by any widely used international case definition, presented very similarly to afebrile Zika cases, though some exhibited warning signs of disease severity. The presence of arthralgia, the presence of basophilia, and the absence of fever were the most important model-based predictors of chikungunya, dengue, and Zika, respectively. Interpretations These findings substantially update our understanding of dengue, chikungunya, and Zika in children while identifying various clinical features that could improve differential diagnoses. The occurrence of afebrile dengue warrants reconsideration of current case definitions. Funding US National Institutes of Health R01AI099631, P01AI106695, U01AI153416, U19AI118610. Research in context Evidence before this study: Dengue, chikungunya, and Zika are mosquito-borne diseases that co-occur in tropical and subtropical settings and give rise to fever, rash, and a variety of other clinical features. We reviewed the most widely used international case definitions for the three diseases – established by either the World Health Organization (WHO) or the Pan American Health Organization (PAHO); PAHO’s 2022 report on differential diagnosis and treatment options for dengue, chikungunya, and Zika; and the 80 studies underlying PAHO’s diagnostic recommendations. The available evidence suggests that dengue, chikungunya, and Zika have a broad and overlapping set of clinical manifestations that hamper differential diagnosis, and hence case management, in the absence of definitive laboratory testing. This similarity in disease presentation is believed to be especially characteristic of the first few days of illness. Most of the studies on the diseases’ clinical manifestations are in adult populations, and these studies constitute the main evidence base for the existing case definitions. For example, only one of the 80 studies summarized in PAHO’s recent report provided direct comparisons of the clinical features across cases experiencing dengue, chikungunya, and Zika, and that study mainly focused on adults. Disease presentation is more non-specific in children and adolescents than in adults, further impeding differential diagnoses in pediatric populations. Current guidelines suggest that the presence of thrombocytopenia, progressive increases in hematocrit, and leukopenia tend to distinguish dengue from chikungunya and Zika; that arthralgia is more common in chikungunya; and that pruritis is more common in Zika. Fever is considered a defining feature of dengue, such that all case definitions in widespread use for the disease require that patients exhibit fever. However, existing but limited evidence suggests that dengue cases can very rarely present without fever. Added value of this study: This study follows a cohort of Nicaraguan children through multiple dengue epidemics, two large chikungunya epidemics, and one explosive Zika epidemic. By synthesizing 18 years’ worth of primary care medical records, we find clinically meaningful differences in the prevalence of many clinical features, including by day of illness and across age, but not by sex. In addition to verifying the clinical features PAHO identified as key distinguishing features, we also identified others, including papular rash, nausea, hemorrhagic manifestations, abdominal pain, and basophilia, that could aid differential diagnoses. As the PAHO report is based on a multitude of studies with varied age ranges, health care accessibility, overall research quality, and patient populations, this study is a complementary and important counterpart that draws from a single, well-characterized source population. Further, we identified 62 laboratory-confirmed cases of afebrile dengue (7·2% of all dengue cases since we started testing any suspected case exhibiting afebrile rash). The disease manifestations of afebrile dengue cases were generally clinically indistinguishable from afebrile Zika, although several displayed warning signs of severity. We found that cases of the three diseases exhibited different temperature dynamics across the acute period of illness. Machine learning models were best able to distinguish chikungunya (an alphaviral disease) from dengue and Zika (flaviviral diseases) based on clinical features alone. Our dengue model performed well, especially in classifying febrile dengue cases. However, our Zika model struggled to properly distinguish afebrile dengue cases from afebrile Zika cases, likely due to their very similar and minimal disease presentation. Implications of all the available evidence: Despite clinical overlap in the pediatric manifestations of dengue, chikungunya, and Zika, we identify meaningful differences in their presentation and in laboratory markers that can be leveraged to improve diagnoses in the absence of definitive laboratory-based diagnostic testing. Afebrile dengue should be studied more and incorporated into future case definitions, as not accounting for its existence can impede surveillance, laboratory testing strategies, clinical management, and research efforts.
- Open Access
- 26 July 2024
- Published by Consejo Nacional de Rectores in Revista Científica Estelí
- No. 50,p. 70-85
Impacto de las variantes genéticas del SARS-CoV-2 en la hospitalización de pacientes con COVID-19 procedentes de la vigilancia nacional del Ministerio de Salud de Nicaragua, marzo 2020 – septiembre 2022
SARS-CoV-2 spread rapidly around the world, causing high morbidity and mortality, making genome sequencing essential. Numerous studies have shown how variants can influence hospitalization. This study aimed to identify the impact of SARS-CoV-2 genetic variants on the probability of hospitalization. A total of 1069 samples from COVID-19 patients across the country were sequenced using Illumina and Oxford Nanopore technologies. Descriptive analyses and logistic regression models were performed to determine associations between virus characteristics and the risk of hospitalization. The main results showed that the most frequent variants were Omicron and Delta (21.32%) and 19B (21.2%). The less common variants were 21C (Epsilon) and 21H (Mu). Mutations were identified in the N, M, ORFs, and S regions of the SARS-CoV-2 genome, including the S:D614G mutation. Significant differences were found in the age of people infected with different variants. There was a negative association between increasing age and the risk of infection with the 19B variant, and a positive association with the 20B and Delta variants. Additionally, associations were found between the 20A, 20B, 20C, and Delta variants and the risk of hospitalization. Age was a determining factor in the risk of infection by certain variants. Some variants increased the risk of hospitalization, and age, in combination with the genetic characteristics of the variants, influenced this risk. The study concludes that mutations of epidemiological importance were identified, especially the S:D614G mutation, and that certain mutations and genetic characteristics of the virus can confer a higher risk of hospitalization.
- 26 July 2024
- Published by Consejo Nacional de Rectores in Revista Científica Estelí
- No. 50,p. 70-85
Open AccessImpacto de las variantes genéticas del SARS-CoV-2 en la hospitalización de pacientes con COVID-19 procedentes de la vigilancia nacional del Ministerio de Salud de Nicaragua, marzo 2020 – septiembre 2022
SARS-CoV-2 spread rapidly around the world, causing high morbidity and mortality, making genome sequencing essential. Numerous studies have shown how variants can influence hospitalization. This study aimed to identify the impact of SARS-CoV-2 genetic variants on the probability of hospitalization. A total of 1069 samples from COVID-19 patients across the country were sequenced using Illumina and Oxford Nanopore technologies. Descriptive analyses and logistic regression models were performed to determine associations between virus characteristics and the risk of hospitalization. The main results showed that the most frequent variants were Omicron and Delta (21.32%) and 19B (21.2%). The less common variants were 21C (Epsilon) and 21H (Mu). Mutations were identified in the N, M, ORFs, and S regions of the SARS-CoV-2 genome, including the S:D614G mutation. Significant differences were found in the age of people infected with different variants. There was a negative association between increasing age and the risk of infection with the 19B variant, and a positive association with the 20B and Delta variants. Additionally, associations were found between the 20A, 20B, 20C, and Delta variants and the risk of hospitalization. Age was a determining factor in the risk of infection by certain variants. Some variants increased the risk of hospitalization, and age, in combination with the genetic characteristics of the variants, influenced this risk. The study concludes that mutations of epidemiological importance were identified, especially the S:D614G mutation, and that certain mutations and genetic characteristics of the virus can confer a higher risk of hospitalization.
- 29 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (749) , eadn2199
Primary exposure to Zika virus is linked with increased risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1
Infection with any of the four dengue virus serotypes (DENV1–4) can protect against or enhance subsequent dengue depending on preexisting antibodies and infecting serotype. Additionally, primary infection with the related flavivirus Zika virus (ZIKV) is associated with increased risk of DENV2 disease. Here, we measured how prior DENV and ZIKV immunity influenced risk of disease caused by DENV1–4 in a pediatric Nicaraguan cohort. Of 3412 participants in 2022, 10.6% experienced dengue cases caused by DENV1 ( n = 139), DENV4 ( n = 133), DENV3 ( n = 54), DENV2 ( n = 9), or an undetermined serotype ( n = 39). Longitudinal clinical and serological data were used to define infection histories, and generalized linear and additive models adjusted for age, sex, time since last infection, and year, and repeat measurements were used to predict disease risk. Compared with flavivirus-naïve participants, primary ZIKV infection was associated with increased risk of disease caused by DENV4 (relative risk = 2.62, 95% confidence interval: 1.48 to 4.63) and DENV3 (2.90, 1.34 to 6.27), but not DENV1 infection. Primary DENV infection or DENV followed by ZIKV infection was also associated with increased risk of DENV4 disease. We reanalyzed 19 years of cohort data and demonstrated that prior flavivirus immunity and antibody titer had distinct associations with disease risk depending on incoming serotype. We thus find that prior ZIKV infection, like prior DENV infection, is associated with increased risk of disease with certain DENV serotypes. Cross-reactivity among flaviviruses should be considered when assessing vaccine safety and efficacy.
- 29 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (749) , eadn2199
Primary exposure to Zika virus is linked with increased risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1
Infection with any of the four dengue virus serotypes (DENV1–4) can protect against or enhance subsequent dengue depending on preexisting antibodies and infecting serotype. Additionally, primary infection with the related flavivirus Zika virus (ZIKV) is associated with increased risk of DENV2 disease. Here, we measured how prior DENV and ZIKV immunity influenced risk of disease caused by DENV1–4 in a pediatric Nicaraguan cohort. Of 3412 participants in 2022, 10.6% experienced dengue cases caused by DENV1 ( n = 139), DENV4 ( n = 133), DENV3 ( n = 54), DENV2 ( n = 9), or an undetermined serotype ( n = 39). Longitudinal clinical and serological data were used to define infection histories, and generalized linear and additive models adjusted for age, sex, time since last infection, and year, and repeat measurements were used to predict disease risk. Compared with flavivirus-naïve participants, primary ZIKV infection was associated with increased risk of disease caused by DENV4 (relative risk = 2.62, 95% confidence interval: 1.48 to 4.63) and DENV3 (2.90, 1.34 to 6.27), but not DENV1 infection. Primary DENV infection or DENV followed by ZIKV infection was also associated with increased risk of DENV4 disease. We reanalyzed 19 years of cohort data and demonstrated that prior flavivirus immunity and antibody titer had distinct associations with disease risk depending on incoming serotype. We thus find that prior ZIKV infection, like prior DENV infection, is associated with increased risk of disease with certain DENV serotypes. Cross-reactivity among flaviviruses should be considered when assessing vaccine safety and efficacy.